3.2: Innovation Ecosystem

3.2.1: Institution has created an ecosystem for innovations and has initiatives for creation and transfer of knowledge

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :09/01/2020

(21) Application No.202031001060 A
(43) Publication Date : 16/07/2021

(54) Title of the invention : BENZOTROPOLONE COMPOUNDS-AMINO ACID BILAYERED FORMULATION AN AID TO NEUROPROTECTION

(51) International classification	:A61K0031198000, A61K0036820000, A23L0033105000, A61K0031436000, A61K0009200000
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No Filing Date	:NA :NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number Filing Date	:NA :NA
(62) Divisional to Application Number Filing Date	:NA :NA

(71)**Name of Applicant :**
1)INDIAN INSTITUTE OF TECHNOLOGY KHARAGPUR
Address of Applicant :Indian Institute of Technology Kharagpur, Kharagpur, 721302, Dist - Midnapore, State of West Bengal, India
(72)**Name of Inventor :**
1)BHANDARI, Koushik
2)DE, Baishakhi
3)GOSWAMI, Tridib Kumar
4)KATAKAM, Prakash

(57) Abstract :
The present invention relates to a bilayered nutraceutical tablet formulation comprising theaflavins, L-theanine and caffeine which synergistically boost neuroprotection and prevent the early onset of Alzheimer's disease multi modally.

No. of Pages : 46 No. of Claims : 10

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :28/02/2019

(21) Application No.201941007807 A
(43) Publication Date : 24/05/2019

(54) Title of the invention : TRANSDERMAL PATCHES OF LAMIVUDINE AND STAVUDINE FOR FOR EXTENDED RELEASE

(51) International classification :A61K9/7038
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)PRAKASH KATAKAM
Address of Applicant :H.No.8/LIGH-1, Udaya Nagar Colony, S.R.Nagar, Hyderabad Telangana India
(72)**Name of Inventor :**
1)NARASIMHA RAO RAMA
2)PRAKASH KATAKAM
3)SHANTA KUMARI ADIKI
4)SHAIK ABDUL RAHAMAN
5)VISHVNATH BHAGWANRAO BHARKAD

(57) Abstract :
The present invention relates to the preparation of transdermal patches of combined antiretroviral drugs, lamivudine and stavudine. The present invention maily related to the field of pharmaceuticals specific to drug delivery field. More particularly application of this pared controlled release transdermal patches of antiretroviral drugs; lamivudine and stavudine for transdermal administration. The invention relates to preparation of transdermal patches by solvent casting technique using polymer blends of hydroxypropyl methyl cellulose (HPMC), ethylcellulose (EC) and cellulose acetate (CA) in different ratios of 1:0, 1:2.66, 1:4 and1:8 as film formers and drugs in different weight ratios. The invention relates to characterization of prepared transdermal patches for tensile strength, elongation, water vapour transmission, water vapour absorption, drug-polymer compatibility, In-vitro drug release and accelerated physical stabiliity studies. The studies demonstrated successful preparation of transdermal patches and effect of polymer blends (HPMC, EC and CA) in various ratios on drug release. The WVT was between 0.3557±0.063 and 0.4980±0.013 and the WVA varied between 41.04±2.26% and 6.09±3.46% after 7 days. The folding endurance was found between 273±3.37 and 292±2.23 number of times of folding. The flatness for all the patches was 100%. SEM analysis showed the surface of patch with smooth and uniform throughout. The FTIR and thermograms showed no drug-polymer interactions. The diffractogram of lamivudine exhibited a series of intense peaks at 21.387, 24.877 and 31.420 which were indicative of crystalline nature of lamivudine. Similarly peaks were observed at 10.083, 16.843, 16.843, 18.732, 22.366, 24.143 and 28.382 which correspond to stavudine. For the tested formulation (F9) no specific peaks of both drugs were obtained. Formulation F9 showed better in vitro diffusion release of drugs up to 14 h than that of F1 and F5. Formulation F9 showed extended release of lamivudine an stavudine with 98.33±1.24% and 96.25±2.26% respectively. Formulation F1 released lamivudine (98.41±1.37%) and stavudine (98.86±2.36%) for 8 h. Formulation F5 showed lamivudine release of 96.21±1.56% and stavudine release of 97.23±1.87% for 13 h. In all the cases the drug diffusion was reciprocal to the polymer concentration in the formulations. All the formulations followed zero order drug release kinetics. Formulation F9 showed higher rate of drug release compared to that of other formulations. The higher correlation coefficient values (>0.955) of Higuchi and Korsmeyer-Peppas plots. Similarity factor (f2) for optimized formulation F9 compared before and after stability testing was found to be 86.64. The drug content of the formulation F9 before and after the accelerated stability studies was found 98.27±5.26% and 96.58±3.47% respectively. Student t-test was conducted on drug content and the value obtained was 0.28 which was lesser than the table value of 2.57 at 95% confidence limits. There was no significant difference observed in the drug content uniformity before and after the stability studies. The prepared transdermal patches loaded with lamivudine and stavudine could be successfully employed for reducing toxicity.

No. of Pages : 26 No. of Claims : 7

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

TCA- PHARMA Series for Semester - V (T.Y. B-PHARMACY)

1	Pharmacology - II
2	Industrial Pharmacy I
3	Pharmaceutical Jurisprudence
4	Medicinal Chemistry II
5	Pharmacognosy and Phytochemistry II

Scan this QR code & get sample eBooks free of TECHNICAL PUBLICATIONS

Download APP in Play Store

Available at all leading booksellers

ONLINE SELLER

amazon Flipkart

Published by :

TECHNICAL PUBLICATIONS
SINCE 1993 An Up-Thrust for Knowledge

Find us
Website : www.technicalpublications.org
https://www.facebook.com/technicalpublications
Amit Residency, Office No.1, 412, Shanwar Peth, Pune - 411030, M.S. INDIA
Ph.: +91-020-24495496/97 | Email : sales@technicalpublications.org

Medicinal Chemistry - II

T.Y. B-PHARMACY SEM V

TCA PHARMA

A Guide for Pharmacy Students

PCI Syllabus

Sub. Code : BP501T



Medicinal Chemistry - II

- T.Y. B-Pharmacy Sem V • Covers Entire Syllabus
- Exact Answers & Solutions • Question - Answer Format
- Solved Sample Papers As Per New Question Paper Pattern of PCI Scheme
- Multiple Choice Questions with Answers

TECHNICAL PUBLICATIONS
An Up-Thrust for Knowledge

Dr. Pallavi A. Kamble
Amit N. Panaskar
Parag G. Ingole

first edition : feb. 2021

Price : ₹ 295/-

ISBN 978-93-90041-04-6

TCA - PHARMA Series for Semester - VI (Third Year B-PHARMACY)

1. Medicinal Chemistry - III
2. Pharmacology - III
3. Herbal Drug Technology
4. Biopharmaceutics & Pharmacokinetics
5. Pharmaceutical Biotechnology
6. Pharmaceutical Quality Assurance

Published by :
TECHNICAL PUBLICATIONS
SINCE 1993 An Up-Thrust for Knowledge

Find us
Website : www.technicalpublications.org
https://www.facebook.com/technicalpublications
Amit Residency, Office No.1, 412, Shaniwar Peth, Pune - 411030, M.S. INDIA.
Ph.: +91-020-24495496/97 | Email : sales@technicalpublications.org

Medicinal Chemistry - III

Third Year B-PHARMACY SEM VI

TCA PHARMA
A Guide for Pharmacy Students

Medicinal Chemistry - III

PCI Syllabus

Sub. Code : BP601T



- Third Year B-Pharmacy Sem VI • Covers Entire Syllabus
- Question - Answer Format • Exact Answers & Solutions
- Sample Papers As Per New Question Paper Pattern of PCI Scheme
- Multiple Choice Questions with Answers

TECHNICAL PUBLICATIONS
SINCE 1993 An Up-Thrust for Knowledge

Dr. Pallavi A. Kamble
Priyanka B. Parekar
Dr. Manisha S. Kedar
Amit N. Panaskar

first edition : feb. 2022
Price : ₹ 210/-
ISBN 978-93-90770-59-5

SUSTAINABLE MANUFACTURING TECHNOLOGIES:
ADDITIVE, SUBTRACTIVE, AND HYBRID

CRC Press
Taylor & Francis Group

Additive Manufacturing Processes in Biomedical Engineering

Advanced Fabrication Methods and Rapid Tooling Techniques

EDITED BY

Atul Babbar
Ankit Sharma
Vivek Jain
Dheeraj Gupta



1 Recent Advancements of Additive Manufacturing for Patient-Specific Drug Delivery

Prakash Katakam[1], *Shanta Kumari Adiki*[2], *and Soumya Ranjan Satapathy*[3]

[1] Indira College of Pharmacy, Nanded, India

[2] Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Hyderabad, Telangana, India

[3] DFE Pharma India Private Limited, Hyderabad, Telangana, India

ABBREVIATIONS

3DP Three dimensional printing; 4DP Four dimensional printing; AM Additive manufacturing; API Active pharmaceutical ingredient; ASTM American Society for Testing and Materials; CAD Computer-aided design; CBER Center for Biologics Evaluation and Research; CDRH Center for Devices and Radiological Health; CLIP Continuous layer interface production; DED Directed Energy Deposition; DLP Digital light processing; DMLS Direct metal laser sintering; DOD drop-on-demand; EBM Electron beam melting; EC Ethylcellulose; FDCT fixed-dose combination therapy; FDM Fused deposition modeling; GMP Good manufacturing practice; LOM Laminated object manufacturing; MEMS Micro-electro-mechanical system; MIT Massachusetts Institute of Technology; MJ Material jetting; NHS National Health Service; NIL Nanoimprint lithography; OVJP organic vapor jet printing; PAM Pressure-assisted microsyringe; PAT Process analytical technology; PAT process analytical technology; PEG Polyethylene glycol; PEO Polyethylene oxide; PoC Point of care; PLGA polylactide-co-glycolide; PVA Polyvinyl alcohol; SDL Selective deposition lamination; SHS Selective heat sintering; SLM Selective laser melting; IJP Inkjet printing; SLA Stereolithography; SLS Selective laser sintering; SMP shape memory polymer; TIJ thermal inkjet; UAM ultrasonic additive manufacturing; US FDA U.S. Food and Drug Administration

DOI: 10.1201/9781003217961-1

RULA AWARDS

"Your Passion, Our Vision"

RULA
INNOVATION
&
BETTERMENT
EXCELLENCE
AWARD

FOR INTERNATIONAL INNOVATION & BETTERMENT EXCELLENCE IN TECHNICAL RESEARCH,

EXCELLENT YOUNG RESEARCHER IN PHARMACEUTICAL CHEMISTRY

Presented to

PALLAVI ASHOK KAMBLE

At Grandeur Hall, Hotel Breeze Residency, Trichy, Tamilnadu, India on 12th November of 2018 powered by,

Rn. S. ABUTHAHIR
Director
IJRULA &
RULA AWARDS

IJRULA

UMC
United Medical Council

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :07/05/2018

(21) Application No.201821017066 A
(43) Publication Date : 25/05/2018

(54) Title of the invention : "SYNTHESIS AND USE OF NOVEL FLAVONOL DERIVATIVES AGAINST LEUKEMIA".

(51) International classification	:A61K 31/00
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No	:NA
Filing Date	:NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number	:NA
Filing Date	:NA
(62) Divisional to Application Number	:NA
Filing Date	:NA

(71)**Name of Applicant :**
1)DR. S.J.WADHER
Address of Applicant :SCHOOL OF PHAMACY, SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY, NANDED, MAHARASHTRA, 431606 INDIA. Maharashtra India
(72)**Name of Inventor :**
1)DR. S.J.WADHER
2)PALLAVI.A.KAMBLE

(57) Abstract :
ABSTRACT The present invention relates to novel flavonol derivative and process of preparation thereof. The present invention also relates to activity of novel flavonol compound in acute myeloid leukemia. From the results, the compound D6 is found to be more potent with the IC50of 0.0062μM/ml. 6.25 μg/ml 12.5 μg/ml 25 μg/ml 50 μg/ml 100μg/ml Fig.l Effect of Compound D6 on HL60 cell lines at different concentrations

No. of Pages : 11 No. of Claims : 7

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :01/05/2019

(21) Application No.201941017288 A
(43) Publication Date : 10/05/2019

(54) Title of the invention : MUCOADHESIVE MULTI-UNIT MINI PATCHES (MMMP) IN ENTERIC COATED CAPSULES FOR CONTROLLED RELEASE OF LANSOPRAZOLE

(51) International classification :C07K16/00
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)SHANTA KUMARI ADIKI
Address of Applicant :Nirmala College of Pharmacy, Atmakur, Mangalagiri 522503, Guntur Andhra Pradesh India
(72)**Name of Inventor :**
1)SHANTA KUMARI ADIKI
2)SANTHISREE VEMULAPALLI
3)PRAKASH KATAKAM

(57) Abstract :
The present invention maily related to the field of pharmaceuticals specific to drug delivery field. The present invention relates to the formulation and evaluation of oral mucoadhesive multi-unit mini patches (MMMP) of lansoprazole (LAN) for extended release. More particularly application of this specification is formulate and evaluate MMMP in enteric coated capsules for extended release of lansoprazole using chitosan in combination with xanthan gum, guar gum, tragacanth or acacia used in the ratios of 19:1, 9:1, 4:1, 1.5:1 and 0.66:1 thereof employing 2% acetic acid as solvent for chitosan, purified water as solvent for natural gum polymers and glycerin 0.12 mL as plasticizer. The invention relates to punching of patches into MMMP with 0.5 mm diameter and filling into hard glatin capsules and further treating the capsules with enteric coating polymers. The invention relates to characterization of prepared MMMP for surface texture, thickness, folding endurance, moisture content, moisture uptake, mucoadhesive strength, drug content uniformity, In-vitro drug release and accelerated physical stabiliity studies. The SEM photographs further showed the rough to smooth pattern of surfaces of patches. The thickness of MMMP found between 43.62±0.27 and 49.53±0.11 m. Mean weight of mini-patch was measured and found between 13.81+0.14 and 14.94+0.15 mg. The percentage of swelling was between 215±5.39 and 473±6.72. The moisture content was between 1.04±0.06 and 2.67±0.24. The mucoadhesion in terms of time reequired to detach all the MMMP from mucosal surface was found between 5.5+0.2 and 12.3+0.6 h. Percentage of drug content uniformity was between 95.08±3.42% and 99.16±4.73% for all formulations. The FTIR and DSC spectra indicated no drug-poymer interactions. The in vitro dissolution studies showed extended release of LAN from MMMP in pH 6.8 phosphate buffer where as no significant of drug release found in acidic environment showing that MMMP in enteric coated capsules could be employed to delivery LAN to intestine directly. Formulations LXF5, LGF5, LTF5 and LAF5 were optimized based on physical characteristics and in vitro drug release patterns. In all the cases the drug dissolution was reciprocal to the polymer concentration in the formulations. Among all natural polymers employed in this specification the decreasing order of drug release from the polymers was Xanthan gum > Tragacanth > Guar gum > Acacia. Accelerated stability studies showed no significant change ($p < .05$) in drug content and dissolution profile of all optimized formulations before and after the test. The prepared mucoadhesive multiple-unit mini patches (MMMP) in enteric coated capsules for controlled release of lansoprazole using natural polymers and could be successfully employed for intestinal delivery while minimizing drug degradation and providing extended release of the drug.

No. of Pages : 30 No. of Claims : 7

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :06/06/2018

(21) Application No.201841021204 A
(43) Publication Date : 15/06/2018

(54) Title of the invention : LIPOSOMES OF COMBINED LAMIVUDINE AND STAVUDINE FOR CONTROLLED RELEASE

(51) International classification	:A61K 9/00	(71)**Name of Applicant :**
(31) Priority Document No	:NA	**1)PRAKASH KATAKAM**
(32) Priority Date	:NA	Address of Applicant :H.No.8/LIGH-1, Udaya Nagar Colony, S.R.Nagar, Hyderabad Andhra Pradesh India
(33) Name of priority country	:NA	(72)**Name of Inventor :**
(86) International Application No	:NA	**1)NARASIMHA RAO RAMA**
Filing Date	:NA	**2)PRAKASH KATAKAM**
(87) International Publication No	: NA	**3)SHAIK ABDUL RAHAMAN**
(61) Patent of Addition to Application Number	:NA	**4)SHANTA KUMARI ADIKI**
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

(57) Abstract :
The present invention relates to the preparation of multilamellar liposomes of combined antiretroviral drugs, lamivudine and stavudine. The present invention maily related to the field of pharmaceuticals specific to drug delivery field. More particularly lication of this prepared controlled release liposomes of antiretroviral drugs; lamivudine and stavudine for oral and parenteral administration. The invention relates to preparation of liposomes by thin film hydration technique using soya lecithin, cholesterol and tocopheryl acetate and drugs in different weight ratios. The invention relates to characterization of prepared liposomes for size, shape, entrapment efficiency, in vitro drug release and physical stability. The studies demonstrated successful preparation of liposomes and effect of soya lecithin:cholesterol weight ratio on entrapment efficiency and on drug release. Maximum entrapment efficiency was found 88.53±0.578%. The prepared liposomes were found to have uniform size distribution. The percentage cumulative drug release from the optimized batch was 99.62±1.02% after 11 h of diffusion studies. Stability studies showed maximum percent drug retention at refrigerated temperature (2€“8°C). The prepared liposomes loaded with lamivudine and stavudine provided increased solubility and protection against hostile environment of gastrointestinal tract and parenteral us and could be successfully employed for reducing toxicity.

No. of Pages : 20 No. of Claims : 7

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :08/08/2017

(21) Application No.201741028061 A
(43) Publication Date : 18/08/2017

(54) Title of the invention : BIOPLASTICS FROM BLENDS OF CELLULOSE ACETATE BUTYRATE AND THERMOPLASTIC STARCH

(51) International classification	:C08L1/00,C08L101/00; C08L101/16
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No	:NA
Filing Date	:NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number	:NA
Filing Date	:NA
(62) Divisional to Application Number	:NA
Filing Date	:NA

(71)**Name of Applicant :**
1)SUPRIYA CHATLA
Address of Applicant :Department of Biotechnology, Nirmala College of Pharmacy, Atmakur, Mangalagiri 522503, Guntur, Andhra Pradesh India
(72)**Name of Inventor :**
1)SUPRIYA CHATLA
2)SHANTA KUMARI ADIKI
3)SHAIK ABDUL RAHAMAN
4)PRAKASH KATAKAM
5)DEVISWETHA VISHNUBHATLA
6)SHAIK SUNAINA
7)MEGHANA YAMANA
8)SRIVIDYA GUDIMEDLA

(57) Abstract :
The present invention relates to the preparation of bioplastics from a blend of cellulose acetate butyrate and thermoplastic starch (TPS). More particularly application of this prepared bioplastic polymers for application as plastic materials by further processing. This invention relates to a blend of 60-90% w/w cellulose acetate butyrate with 5-10% w/w thermo plastic starch with a plasticizer and other additives to improve its tensile strength, elasticity, thermo stability, UV stability, antimicrobial, antioxidant properties of bioplastics and to enhance the performance of bioplastics. The prepared bioplastics showed advantageous attributes includes enough tensile strength, thermo stability, weight holding capacity, antimicrobial UV stability and antioxidant properties. The prepared biodegradable bioplastic films can be tailored for particular uses. These bioplastic films can be used to manufacture the trays, blister foils and containers used to pack the fruits, vegetables, eggs and meat; bottles for soft drinks and dairy products.

No. of Pages : 18 No. of Claims : 8

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :08/08/2017
(21) Application No.201741028061 A
(43) Publication Date : 18/08/2017

(54) Title of the invention : BIOPLASTICS FROM BLENDS OF CELLULOSE ACETATE BUTYRATE AND THERMOPLASTIC STARCH

(51) International classification :C08L1/00,C08L101/00; C08L101/16
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)SUPRIYA CHATLA
Address of Applicant :Department of Biotechnology, Nirmala College of Pharmacy, Atmakur, Mangalagiri 522503, Guntur, Andhra Pradesh India
(72)**Name of Inventor :**
1)SUPRIYA CHATLA
2)SHANTA KUMARI ADIKI
3)SHAIK ABDUL RAHAMAN
4)PRAKASH KATAKAM
5)DEVISWETHA VISHNUBHATLA
6)SHAIK SUNAINA
7)MEGHANA YAMANA
8)SRIVIDYA GUDIMEDLA

(57) Abstract :
The present invention relates to the preparation of bioplastics from a blend of cellulose acetate butyrate and thermoplastic starch (TPS). More particularly application of this prepared bioplastic polymers for application as plastic materials by further processing. This invention relates to a blend of 60-90% w/w cellulose acetate butyrate with 5-10% w/w thermo plastic starch with a plasticizer and other additives to improve its tensile strength, elasticity, thermo stability, UV stability, antimicrobial, antioxidant properties of bioplastics and to enhance the performance of bioplastics. The prepared bioplastics showed advantageous attributes includes enough tensile strength, thermo stability, weight holding capacity, antimicrobial UV stability and antioxidant properties. The prepared biodegradable bioplastic films can be tailored for particular uses. These bioplastic films can be used to manufacture the trays, blister foils and containers used to pack the fruits, vegetables, eggs and meat; bottles for soft drinks and dairy products.

No. of Pages : 18 No. of Claims : 8

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

INTELLECTUAL PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

सत्यमेव जयते
GOVERNMENT OF INDIA

Controller General of Patents,Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

(12) PATENT APPLICATION PUBLICATION
(19) INDIA

(21) Application No. : 4093/CHE/2012

(22) Date of filing of Application :01/10/2012

(43) Publication Date : 04/04/2014
Journal No. - 14/2014

(54) Title of the invention : STARCH TARTRATE AS NOVEL SUPERDISINTEGRANT IN FORMULATION AND EVALUATION OF FAST DISINTEGRATING TELMISARTAN TABLETS

(51) International classification :A61K9/00
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)KATAKAM PRAKASH
Address of Applicant :H.NO.8/LIGH-1, UDAYA NAGAR COLONY, S.R. NAGAR, HYDERABAD - 500 038 Andhra Pradesh India
(72)**Name of Inventor :**
1)R. NARESH BABU (India)
2)RAMESH BOTCHA (India)

(57) Abstract :
Disintegration is a most important step in absorption of poorly soluble drugs from tablet dosage form. Telmisartan is an Anti-hypertensive drug which is insoluble in water with bioavailability is only 42%. The objective of present invention is to synthesize starch tartrate as novel superdisintegrant by chemical modification of starch upon treating with tartaric acid. In the present invention starch tartrate, a novel polymer is synthesized, characterized and evaluated as disintegrant in tablets prepared by direct compression method. Fast disintegrating tablets of telmisartan 200mg were prepared by direct compression method incorporating starch tartrate as disintegrant at 5, 10, 15 % strength in the formula. The tablets were evaluated for the quality control parameters like weight variation, hardness, thickness, friability and drug content. The prepared tablets of starch tartrate have shown faster disintegration and dissolution profiles compared to those prepared using crosscarmellose sodium and sodium starch glycolate as superdisintegrants. The tablets were also evaluated in comparison to commercial brands.

Number of Pages = 20

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :12/12/2011

(21) Application No.4320/CHE/2011 A
(43) Publication Date : 21/06/2013

(54) Title of the invention : NOVEL APPLICATION OF SODIUM ALGINATE AS BIODEGRADABLE CARRIER IN CONTROLLED RELEASE SUBGINGIVAL DELIVERY FILMS

(51) International classification :A61K
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No :NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)KATAKAM PRAKASH
Address of Applicant :H.NO.8/LIGH-1, UDAYA NAGAR COLONY, S.R. NAGAR, HYDERABAD - 500 038, AP, INDIA.
(72)**Name of Inventor :**
1)CHANDU BABU RAO
2)SHANTA KUMARI KATAKAM
3)S. A. RAHAMAN

(57) Abstract :
The present invention relates to novel application of sodium alginate as biodegradable carrier in controlled release subgingival delivery films. More particularly, the present invention provides preparation and evaluation cephalexin controlled release subgingival films using biodegradable sodium alginate polymer. The present invention provides the equipment necessary for the present invention was fabricated and employed for casting of sodium alginate subgingival films. Subgingival films of drug:polymer in various proportions (10:90, 25:75, 50:50 and 75:25) were prepared using solvent casting method. A 10%w/v CaCl2 solution was used for gelation of the films. As polymer concentration is increased the smoothness of the films increased. The thickness of films varied from 146±5 to 312± 15 µm which is well below the recommended thickness (0.24 µg/ml) up to 120 hrs which is sufficient to inhibit the growth of the micro-organisms. The rate of drug release was inversely proportional to polymer concentration in the formulations. The low Ki and 'r' values obtained may be due to biphasic drug release pattern. The drug release was due to diffusion only in second phase of dissolution. All the films have shown to have integrity even after 5 days of dissolution studies. The formulations C1 and C2 which contain 90 and 75%w/w of polymer could be employed for controlled delivery of cephalexin for 5 days in subgingival infections. The present invention provide sodium alginate, being a biodegradable polymer is a good choice as drug carrier and all the drugs that are used to treat periodontitis can be employed for local delivery into subgingival cavity using sodium alginate films.

No. of Pages : 14 No. of Claims : 9

Principal
Indira College of Pharmacy,
Vishnupuri, Nanded - 06.

INTELLECTUAL PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

सत्यमेव जयते
GOVERNMENT OF INDIA

Controller General of Patents,Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

(12) PATENT APPLICATION PUBLICATION
(19) INDIA

(21) Application No. : 2076/CHE/2011

(22) Date of filing of Application :20/06/2011

(43) Publication Date : 28/12/2012
Journal No. - 52/2012

(54) Title of the invention : SYNTHESIS OF PIPERAZINE NUCLEUS CONTAINING NOVEL CHALCONE DERIVATIVES AND THEIR ANTIHISTAMINIC ACTIVITY

(51) International classification :C07C
(31) Priority Document No :NA
(32) Priority Date :NA
(33) Name of priority country :NA
(86) International Application No :NA
Filing Date :NA
(87) International Publication No : NA
(61) Patent of Addition to Application Number :NA
Filing Date :NA
(62) Divisional to Application Number :NA
Filing Date :NA

(71)**Name of Applicant :**
1)ABDUL RAHAMAN SHAIK
Address of Applicant :DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, NIRMALA COLLEGE OF PHARMACY, MANGALAGIRI, GUNTUR - 522 502 Andhra Pradesh India
(72)**Name of Inventor :**
1)PRAKASH KATAKAM (India)
2)RAJENDRA PRASAD Y (India)
3)PHANIKUMAR KOLA (India)

(57) Abstract :
Diaryl propene-2-ones, commonly called as chalcones were synthesized (compounds RC1 to RC8) by condensation of 4"-piperazinoacetophenone with different substituted aromatic aldehydes in 40% alkali. The structures of the eight synthesized compounds were established on the basis of elemental analysis, I.R., 1H NMR and mass spectral data. Since these compounds possessed piperazine moiety which is characteristic of many currently available antihistaminic agents, they were evaluated for their antihistaminic activity. Among the compounds tested, RC6 exhibited a much lower IC50 value than the standard drug (mepiramine) at 0.0033 ±0.0002 µM. Other compounds in this series also possessed dose dependent antihistaminic activity.

Number of Pages = 12

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

INTELLECTUAL PROPERTY INDIA
PATENTS | DESIGNS | TRADE MARKS
GEOGRAPHICAL INDICATIONS

सत्यमेव जयते
GOVERNMENT OF INDIA

Controller General of Patents,Designs and Trademarks
Department of Industrial Policy and Promotion
Ministry of Commerce and Industry

(12) PATENT APPLICATION PUBLICATION
(19) INDIA

(21) Application No. : 2296/CHE/2009

(22) Date of filing of Application :22/09/2009

(43) Publication Date : 25/03/2011
Journal No. - 12/2011

(54) Title of the invention : "LONG ACTING FORMULATIONS CONTAINING STAVUDINE"

(51) International classification	:A61K31/00
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No	:NA
Filing Date	:NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number	:NA
Filing Date	:NA
(62) Divisional to Application Number	:NA
Filing Date	:NA

(71)**Name of Applicant :**
1)NARAYANA RAJU PADALA
Address of Applicant :KLR COLLEGE OF PHARMACY, BEHIND CONTRACTORS COLONY, PALONCHA, KHAMMAM DIST- 507 115, ANDHRAPRADESH Andhra Pradesh India
(72)**Name of Inventor :**
1)PADALA NARAYANA RAJU (India)
2)KATAKAM PRAKASH (India)
3)MUNGAMURI LAKSHMI NARASU (India)
4)TADIKONDA RAMA RAO (India)
5)KATAKAM SHANTA KUMARI (India)

(57) Abstract :
The present invention relates to the preparation of extended release dosage forms of stavudine are provided comprising tablets with matrix forming extended release polymer. The tablets were prepared with direct mixing of the drug with extended release polymer and other ingredients. More particularly the present invention relates to a matrix tablet of stavudine and its process for the preparation.

Number of Pages = 14

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

INTELLECTUAL PROPERTY INDIA

Office of Controller General of Patents
Designs, and Trademarks
Indian Patent Information Retrieval System

(IPIRS)

Published Patent Applications

(12) PATENT APPLICATION PUBLICATION
(19) INDIA
(22) Date of filing of Application :26/02/2007

(21) Application No. : 387/CHE/2007
(43) Publication Date : 28/11/2008
Journal No. - 48/2008

(54) Title of the invention : SUSTAINED RELEASE MATRIX TABLETS CONTAINING ZIDOVUDINE

(51) International classification	:A61K9/22
(31) Priority Document No	:NA
(32) Priority Date	:NA
(33) Name of priority country	:NA
(86) International Application No	:NA
Filing Date	:NA
(87) International Publication No	: NA
(61) Patent of Addition to Application Number	:NA
Filing Date	:NA
(62) Divisional to Application Number	:NA
Filing Date	:NA

(71)Name of Applicant :
1)DR. KATAKAM PRAKASH
Address of Applicant :ST. PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES VIDYANAGAR HANAMKONDA WARANGAL 506001 AP. Andhra Pradesh India
(72)Name of Inventor :
1)DR. KATAKAM PRAKASH (India)
2)PADALA NARAYANA RAJU (India)
3)KATAKAM SHANTA KUMARI (India)
4)MELLA SWAPNA (India)

(57) Abstract :
The present invention relates to the sustained release pharmaceutical formulation containing zidovudine. More particularly the present invention relates to a matrix tablet of Zidovudine and its process for the preparation.

Number of Pages = 9

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.

PATENT OFFICE
INTELLECTUAL PROPERTY BUILDING
S.M. Road, Antop Hill, Mumbai-400 037
Te No. (091)(022) 24137701, 24141026 FAX No. 02 24130387
E-mail : mumbai-patent@nic.in
Web Site : www.ipindia.gov.in

सत्यमेव जयते
GOVERNMENT OF INDIA

INTELLECTUAL PROPERTY INDIA
PATENTS DESIGNS TRADE MARKS GEOGRAPHICAL INDICATIONS

Docket NO : 20679
To
DR. S. J. WADHER
SCHOOL OF PHAMACY, SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY, NANDED, MAHARASHTRA, INDIA.

Date/Time : 2018/05/07 12:05:29
Agent Number:

Sr. No.	CBR Number	Reference Number /Application Type	Application Number	Title/Remarks	Amount Paid	Amount Computed
1	8341	ORDINARY APPLICATION Pages:-9 , Claims:-7,Drawings:-0,Abstract:-1,Claims pages:-1	201821017066	"SYNTHESIS AND USE OF NOVEL FLAVONOL DERIVATIVES AGAINST LEUKEMIA".	1750	1750
2		E-2/932/2018-MUM	201821017066	Form2	0	0
3		E-5/787/2018-MUM	201821017066	Form5	0	0
4	8341	E-12/440/2018-MUM	201821017066	Form9	2750	2750
5	8341	R20182013629	201821017066	Form18	4400	4400
Total Amount					8900	8900

Received a sum of Rs. 8900 (Rupees Eight Thousand Nine Hundred only) as under

Payment Mode	Bank Name	Cheque/Draft Number	Cheque/Draft Date	Amount in Rs
Cash	---	---	---	8900

Note: This is electronically generated receipt hence no signature required.

Principal
Indira College of Pharmacy
Vishnupuri, Nanded - 06.